Thrombosis & Hemostasis Summit of North America 2016Apr16. IVC Filters
|
|
- Erika Mason
- 6 years ago
- Views:
Transcription
1 Thrombosis & Hemostasis Summit of North America 2016Apr16 IVC Filters Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Can. Pat. Safety Institute Executive, Thrombosis Canada
2 Disclosures Financial disclosures Off-label use of drugs None No
3 Outline Epidemiology of IVCF use Indications Evidence from clinical trials Complications Suggestions and summary
4 Types of IVC Filters 1. Permanent 2. Temporary A. Retrievable (optional) VENATECH B. Tethered
5 IVC Filters Approved in USA in 2016 Type Filter name Company Permanent Bird s Nest Cook Retrievable (Optional) Greenfield Simon Nitinol TrapEase VenaTech Boston Scientific Bard Cordis Braun
6 IVC Filters Approved in USA in 2016 Type Filter name Company Permanent Bird s Nest Cook Retrievable (Optional) Greenfield Simon Nitinol TrapEase VenaTech ALN Celect Crux Denali Gunther Tulip OptEase OptionElite Boston Scientific Bard Cordis Braun ALN Cook Volcano Bard Cook Cordis Argon
7 IVC Filter Placement in USA 300, , , , , , ,000 50, ,000 49,000 2, Stein Arch Intern Med 2004;164:1541; Smouse Endovasc Today 2010;74; Kuy J Vasc Surg: Ven Lymph 2014:2:15
8 IVC Filters in Acute VTE Rx 263 California hospitals, ,643 patients with acute VTE IVCF in 15% of VTE patients (0-39%) White JAMA Intern Med 2013;173(7):506
9 Cultural differences in IVC Filter use
10 IVC Filters Inserted in 2012 Population in 2012 IVCF placed Germany, France, UK, Italy, Spain 316,600,000 9,070 USA 313,000, , times more Lee Cardiovasc Intervent Radiol 2015;38:1502
11 Regional Variation in IVCF Use Rates of IVCF use/1,000 PE pa<ents 1999 (92à217) 2010 (113à222) New England only region with decrease. Bikdeli J Am Coll Cardiol 2016;67(9):1027
12 Dramatic Increase in IVCF Rates Expanded (off-label) indications Ease of insertion More experienced filter inserters Removable filters must be safer Defensive medicine?financial incentives
13 Dramatic Increase in IVCF Rates Expanded (off-label) indications Ease of insertion More experienced filter inserters Removable filters must be safer Defensive medicine?financial incentives NOT: evidence of benefit evidence of safety
14 Outline Epidemiology of IVCF use Indications Evidence from clinical trials Complications Suggestions and summary
15 What is the purpose of an IVCF?
16 What is the purpose of an IVCF? 1. To prevent PE 2. To prevent fatal PE 3. To prevent fatal and life-threatening PE 4. To prevent fatal and life-threatening PE without causing greater harm than benefit
17 What is the purpose of an IVCF? 1. To prevent PE 2. To prevent fatal PE 3. To prevent fatal and life-threatening PE 4. To prevent fatal and life-threatening PE without causing greater harm than benefit 5. To prevent fatal and life-threatening PE without causing greater harm than benefit and at a cost that is worth it
18 Patients with VTE: 1.Anticoagulation contraindicated 2.In addition to anticoagulation IVC filters Therapeutic indications Primary prophylaxis (no VTE): 1.Trauma 2.Bariatric surgery, orthopedic surgery Prophylactic indications
19 FDA Approved Indications for IVCF 1. Pulmonary thromboembolism when anticoagulant therapy is contraindicated 2. Failure of anticoagulant therapy in thromboembolic diseases 3. Emergency treatment following massive PE when anticipated benefits of conventional therapy are reduced 4. Chronic recurrent PE when anticoagulant therapy has failed or is contraindicated Streiff Thromb Res 2010;125:S128
20 Outline Epidemiology of IVCF use Indications Evidence from clinical trials Complications Suggestions and summary
21 Smoke Spark (N=2) Flame (?)
22 1 st RCT of IVC Filter Use = PREPIC
23 IVC Filter* for Treated Proximal DVT Patients at high risk for PE; anticoagulated >3 mos Outcomes Day 12 No filter (n=200) Filter (n=200) PE 9 (4.8%) 2 (1.0%) 0.03 Death 5 (2.5%) 5 (2.5%) 1.0 P *4 different permanent filters Decousus NEJM 1998;338:409
24 IVC Filter for Treated Proximal DVT Outcomes at Day 12 No filter (n=200) Filter (n=200) All PE 9 (4.8%) 2 (1.0%) 0.03 Asympt PE 4 0 Sympt PE P Fatal PE * 4 0 *autopsy in only 1 Decousus NEJM 1998;338:409
25 IVC Filter for Proximal DVT Patients at high risk for PE; anticoagulated >3 mos Outcomes Day 12 No filter (n=200) Filter (n=200) All PE 9 (4.8%) 2 (1.0%) 0.03 Symptomatic PE 5 (2.5%) 2 (1.0%) 0.25 Death 5 (2.5%) 5 (2.5%) years Symptomatic PE 12 (6.3%) 6 (3.4%) 0.16 Recurrent DVT 21 (12%) 37 (21%) 0.02 Death 40 (20%) 43 (22%) 0.65 P Decousus NEJM 1998;338:409
26 JAMA 2015;313(16): nd RCT of IVC Filter Use = PREPIC-2
27 Retrievable IVCF in PE (PREPIC-2) RCT at 18 centers in France; N=399 Patients with unprovoked PE + DVT/SVT + Age >75 RV dysfunction Active cancer Bilateral or iliocaval DVT Cardiorespiratory failure Anticoagulation Anticoagulation + ALN IVCF 3 mos Mismetti JAMA 2015:313(16):1627
28 Retrievable IVCF in PE (PREPIC-2) RCT at 18 centers in France; N=399 Patients with unprovoked PE + DVT/SVT + >1 additional risk factor(s) Anticoagulation Anticoagulation + ALN IVCF 3 mos 3 mos Anticoagulation (n=199) Anticoagulation + IVCF (n=200)* P Recurrent PE 3 (1.5%) 6 (3%) 0.5 Fatal PE 2 6 DVT Death 6.0% 7.5% 0.55 *21% of filters not removed Mismetti JAMA 2015:313(16):1627
29 2016;4(1): ;4:127 No Class I evidence to support prophylactic IVCF placement in any patient group
30 SIR/SVS/Industry/FDA IVC Filter Study (PRESERVE) Objectives: 1. Document current IVCF practice 2. Evaluate safety and effectiveness Design: prospective, national cohort study with long-term follow-up in ~60 sites Study population: ~2,100 patients (7 filters x >300 patients each), all indications
31 SIR/SVS/Industry/FDA IVC Filter Study (PRESERVE) venogram or IVUS abd film venogram IVCF insertion discharge retrieval 1 mo IVCF not removed venogram or IVUS 3 mos abd film 6 mos (phone) 1 year CT scan 18 mos (phone) 2 years CT scan
32 FDA Approved Indications for IVCF evidence 1. Pulmonary thromboembolism when no anticoagulant therapy is contraindicated 2. Failure of anticoagulant therapy in no thromboembolic diseases 3. Emergency treatment following massive PE when anticipated benefits of no conventional therapy are reduced 4. Chronic recurrent PE when anticoagulant therapy has failed or is contraindicated no
33 What is the purpose of an IVCF? 1. To prevent PE 2. To prevent fatal PE 3. To prevent fatal and life-threatening PE 4. To prevent fatal and life-threatening PE without causing greater harm than benefit 5. To prevent fatal and life-threatening PE without causing greater harm than benefit and at a cost that is worth it Probably vs nothing No evidence No evidence No evidence; estimates show complic>benefit No evidence (There never will be)
34 Outline Epidemiology of IVCF use Indications Evidence from clinical trials Complications Suggestions and summary
35 IVC-Related Complications Procedure-related Access site bleeding 2-4% Misplacement 1-5% Contrast nephropathy 1% Acute embolization Access site thrombosis Short-term Delayed anticoagulation Filter thrombosis 5-40% Filter migration PE 0-1% Long-term Inability to remove (5-20%) DVT Fracture & embolization Perforation (aorta, RPH, etc) IVC thrombosis IVC stenosis Related to long-term anticoagulation Major complications: 3-5% (minimum)
36 Complications of Retrievable IVCFs Systematic review of 37 studies; N=6,834 Mean follow-up only 9.9 mos Complication Filters Frequency DVT 1, % Filter migration 2, % IVC thrombosis or stenosis 4, % Unable to remove 1, % Not removed 5,043 66% Angel JVIR 2011;1522
37 JVIR 2014;25(8):1181 FDA MAUDE (Manufacturer and User Device Experience) : 1,606 reported AEs
38 Complications of IVC Filters FDA MAUDE (Manufacturer and User Device Experience) Complications No. of AEs Perm IVCFs Retrievable IVCFs p All 1,606 13% 87% < Fracture 350 5% 95% < Placement issue % 69% < IVC penetration 228 6% 94% < Migration >2 cm % 79% < Tilt 197 2% 98% < Limb embolization 154 3% 97% < IVC thrombosis 41 20% 80% <0.001 VTE/PE 30 27% 73% <0.007 < < < < < < < < < Andreoli JVIR 2014;25:1181
39 Complications of Retrievable Filters Complications All 1,394 Fracture 334 (24%) Placement issue 219 (16%) IVC penetration >3 cm 214 (15%) Tilt 194 (14%) Migration >2 cm 169 (12%) Limb embolization 150 (11%) IVC thrombosis 33 (2%) VTE/PE 22 (2%) Duodenum 28 Aorta 14 Vertebra 12 RPH 9 Andreoli JVIR 2014;25:1181
40 Strut Penetration with Celect Filters 595 Celect IVCF at U. Chicago Follow-up abdominal CT in 193 (mean 176 days aver inser<on) Strut penetra<on >3 mm (range: 4-9 mm) 55 (29%)* *rate increased with dwell time Bos JVIR 2015;26(1):101
41 Risk of Recovery IVCF Fracture Cleveland Clinic, Recovery filters; 73% not retrieved Dwell time Fracture rate 2 yrs 10% 4 yrs 20% 5.5 yrs 40% Tam JVIR 2012;23:199
42 Tricuspid valve Caval + Aortic thrombosis Spinal canal Right atrium Aorta Duodenum
43 Filter thrombosis à amputation Filter thrombosis Right atrium Pericardial tamponade Caval stenosis
44 What does the IVC look like after a filter is removed? Major head injury Prophylactic IVCF inserted Filter removed at 14 days Died following day (unrelated to filter) Ashley J Trauma 2005;59:847
45 Additional Adverse Consequences of IVCF Placement Unjustified delays in initiating anticoagulant prophylaxis or therapy Risks of long-term anticoagulation related to presence of the filter alone Potential risks during pregnancy, exercise (or hockeyj) Huge costs
46 Long-Term Safety?
47 Outline Epidemiology of IVCF use Indications Evidence from clinical trials Complications Suggestions and summary
48 10 th ACCP Guideline IVCF Use (Therapeutic) 17. In patients with acute DVT or PE who are treated with anticoagulants, we recommend AGAINST the use of an inferior vena cava (IVC) filter [Grade 1B] Kearon Chest 2016;149:315
49 9th ACCP Conference on Antithrombotic Therapy IVC Filter Use (Prophylactic): Recommend AGAINST IVCF as thromboprophylaxis in trauma or spinal cord injury [Grade 2C] Gould - Chest 2012;141(Suppl 1):e227S
50 All IVCFs inserted at Sunnybrook, No. of IVC Filters Not removed Removed 21/yr 60% Mean 21/yr (None prophylactic) 60% removed
51 All IVC Filter Use/Hospital/Year Consecutive patients with filters placed, North America Author, year Group Time period No. IVCF/ yr IVCF retriev Dabbagh, 2010 U. Missouri % Mission, 2010 UCSF Med Center % Meisner, 2012 Stony Brook UH % Eifler, 2013 Northwestern U % Desai, 2014 North-Shore U , % Duffett, 2014 U. Ottawa % Inagaki, 2016 Boston Med Cntr , % Combined 7 major HSC , % Sunnybrook HSC %
52 IVCFs in Trauma at Sunnybrook, Permanent Op<onal No. of IVC Filters Mean 4.1/yr (None prophylactic) 76% removed during trauma admission
53 IVCF Practice in Trauma, Consecutive papers reporting IVCF use in trauma, North America Author, year Location Total IVCF IVCF/yr Proph IVCF/yr IVCF retrieved Helling, 2009 Johnstown, PA % Johnson, 2009 Walter Reed MC % Smoot, 2010 Mayo Clinic % Kalina, 2012 Newark, DE NR 24% Rogers, 2012 Lancaster, PA NR NR % Sarosiek, 2013 Boston, MA % Charlton-Ouw, 2015 UT, Houston ~60 34% Combined 7 centers 1, % Sunnybrook, Toronto % *average/center
54 Single Indication for an IVC Filter Recent PROXIMAL DVT PLUS an absolute contraindication to full anticoagulation
55 NOT Indicators for IVC Filters 1. PE with contraindication to therapeutic anticoagulation (if no DVT) 2. Primary prophylaxis in trauma / major surgery 3. Anticoagulant failure = a contraindication 4. Extensive proximal DVT or VTE with poor cardiopulmonary reserve 5. During catheter-directed management of DVT
56
57 Considering an IVC Filter... The 4 steps (+ 1) 1. Is the indication appropriate? 2. Only use a removable filter 3. Start anticoagulation as soon as it s safe often escalating the dose as bleeding risk 4. Remove filter after therapeutic anticoagulation achieved almost always same admission + Mandatory, regular follow-up of all nonretrieved filters
58 Additional Costs of IVCF in USA Germany, France, UK, Italy, Spain Population in 2012 IVCF placed 316,600,000 ~10,000 USA 313,000,000 >250,000 ~240,000 more filters in USA/yr vs Europe Lee Cardiovasc Intervent Radiol 2015;38:1502 Cost $5,000 Cost $10,000 Additional cost* $1.2 billion $2.4 billion *NOT considering costs of retrieval, complications, medical-legal
59 IVC Filter Use: Summary 1. Exponential increased use past 15 years 2. No evidence of benefit for the indications in which they are used (and there never will be) 3. Many filters are placed for inappropriate indications 4. Most retrievable filters are not removed 5. Retrievable filters can be dangerous if not removed promptly 6. Enormous, unjustified costs
I am NOT: Disclosures. The Problem of the Con-Position Non Thinking! Against New Ideas. Against New Therapies. Against Endovascular Therapies
Inferior Vena Cava Filters: Disclosures A Love /Hate (Mostly Hate) Relationship Lack of Political Correctness Gregory L. Moneta, M.D. Professor and Chief, Vascular Surgery Oregon Health & Science University
More informationInferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski. Department of Surgery Grand Rounds March 24, 2008
Inferior Venacaval Filters Valuable vs. Dangerous Valuable Annie Kulungowski Department of Surgery Grand Rounds March 24, 2008 History of Vena Cava Filters Virchow-1846-Proposes PE originate from veins
More informationIVC Filters: For Whom, Why and When?
IVC Filters: For Whom, Why and When? Dariusz Zawierucha, MD Interventional & Diagnostic Radiology Radiology Associates, PC 1 Disclosures: I have no financial conflicts to disclose. I do not endorse any
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationInferior Vena Cava Filters
Inferior Vena Cava Filters and the American Society of Hematology Choosing Wisely Campaign Kevin P. Hubbard, DO, HMDC MACOI Chief - Division of Specialty Medicine Professor and Chair - Section of Internal
More informationIVC Filters: A new era of responsibility
IVC Filters: A new era of responsibility Stephen L. Wang, MD Lead Physician, KP National IVC Filter Registry Director, IVC Filter Clinic KP Santa Clara Vascular/Interventional Radiology Disclosure of Relevant
More informationClinical Guide - Inferior Vena Cava Filters (Reviewed 2006)
Clinical Guide - Inferior Vena Cava Filters (Reviewed 2006) Principal Developer: V. Oliva Secondary Developers: W. Geerts Background The treatment of choice for deep venous thrombosis (DVT) and pulmonary
More informationInferior Vena Cava Filters- Are they Followed up? By Dr Nathalie van Havre Dr Chamica Wijesinghe Dr Kieren Brown
Inferior Vena Cava Filters- Are they Followed up? By Dr Nathalie van Havre Dr Chamica Wijesinghe Dr Kieren Brown Introduction Trousseau (1868) first described interruption to inferior vena cava (IVC) to
More informationDeep Venous Thrombosis, Pulmonary Embolus and IVC Filters. Michael Meuse, M.D. Vascular and Interventional Radiology
Deep Venous Thrombosis, Pulmonary Embolus and IVC Filters Michael Meuse, M.D. Vascular and Interventional Radiology Pulmonary Embolism and DVT Estimated 570,000 to 650,000 cases of symptomatic PE each
More informationM Johnson Disclosures
2/22/2013 IVC Filters: Current Controversies and the PRESERVE Study Matthew S Johnson MD FSIR Indiana University School of Medicine M Johnson Disclosures Speaking and Teaching Bayer Cook Nordion Research
More informationSpecial comment. (inferior vena cava filter, IVCF) Mobin-Uddin % [4] 1 IVCF
340 Special comment ; ; ; :R543.6 :A :1008-794X(2011)-05-0340-05 The consensus among Chinese interventional experts on the standard of inferior vena cava filter insertion and retrieval Academic Group of
More informationINFERIOR VENA CAVA FILTERS QUIZ 10 QUESTIONS MAY 5, 2014
INFERIOR VENA CAVA FILTERS QUIZ 10 QUESTIONS MAY 5, 2014 QUESTION 1 1. Anatomically Transposition of the IVC is observed in what % of individuals A) 1-5% B).2-.05% C) 3-5% D) 5-10% ANSWER QUESTION 1 Answer
More informationORIGINAL INVESTIGATION. Indications, Complications, and Management of Inferior Vena Cava Filters
LESS IS MORE ORIGINAL INVESTIGATION Indications, Complications, and Management of Inferior Vena Cava Filters The Experience in 952 Patients at an Academic Hospital With a Level I Trauma Center Shayna Sarosiek,
More informationBard Meridian Filter Fracture
Bard Meridian Filter Fracture The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation As Published Publisher Wu, Alex et al. Bard
More informationTHROMBOEMBOLIC EVENTS AFTER IVC FILTER PLACEMENT IN TRAUMA PATIENTS. Lidie Lajoie, MD SUNY Downstate Department of Surgery December 20, 2012
THROMBOEMBOLIC EVENTS AFTER IVC FILTER PLACEMENT IN TRAUMA PATIENTS Lidie Lajoie, MD SUNY Downstate Department of Surgery December 20, 2012 Background Trauma Patients at High Risk for VTE Spain, D.A.,
More informationIVC Filters: Rate of Insertion, Indications, Effects on Prognosis, Evidence Basis for Current Practices. Paul D. Stein, MD
IVC Filters: Rate of Insertion, Indications, Effects on Prognosis, Evidence Basis for Current Practices Paul D. Stein, MD Professor Department of Osteopathic Medical Specialties College of Osteopathic
More informationJ Jpn Coll Angiol, 2009, 49:
Online publication August 27, 2009 1 2 J Jpn Coll Angiol, 2009, 49: 247 254 deep vein thrombosis, thrombolytic therapy, catheter-directed thrombolysis, inferior vena cava filter, pulmonary thromboembolism
More informationSupplementary Online Content
Supplementary Online Content Mismetti P, Laporte S, Pellerin O, Ennezat P-V, Couturaud F, Elias A, et al. Effect of a retrievable inferior vena cava filter plus anticoagulation vs anticoagulation alone
More informationVTE in the Trauma Population
VTE in the Trauma Population Erik Peltz, D.O. February 11 th, 2015 * contributions from Eduardo Gonzalez, M.D. University of Colorado T-32 Research Fellow The problem. VTE - Scope of the Problem One of
More informationInferior Vena Cava Filter Retrieval
Inferior Vena Cava Filter Retrieval Tips on the best methods for retrieving an IVC filter. BY THUONG G. VAN HA, MD Studies have shown that inferior vena cava (IVC) filters are effective in the prevention
More informationVENOUS THROMBOEMBOLISM: DURATION OF TREATMENT
VENOUS THROMBOEMBOLISM: DURATION OF TREATMENT OBJECTIVE: To provide guidance on the recommended duration of anticoagulant therapy for venous thromboembolism (VTE). BACKGROUND: Recurrent episodes of VTE
More informationNew Guidance in AT10 Clive Kearon, MD, PhD,
New Guidance in AT10 Clive Kearon, MD, PhD, Professor, Department of Medicine, McMaster University; Program Director, McMaster Clinical Investigator Program, McMaster University Head, Clinical Thromboembolism
More informationVenous Thromboembolism Prophylaxis: Checked!
Venous Thromboembolism Prophylaxis: Checked! William Geerts, MD, FRCPC Director, Thromboembolism Program, Sunnybrook HSC Professor of Medicine, University of Toronto National Lead, VTE Prevention, Safer
More informationSAFETY AND EFFECTIVENESS OF INFERIOR VENA CAVA FILTERS USED TO PROTECT AGAINST PULMONARY EMBOLUS
TITLE: SAFETY AND EFFECTIVENESS OF INFERIOR VENA CAVA FILTERS USED TO PROTECT AGAINST PULMONARY EMBOLUS AUTHOR: Judith Walsh, MD, MPH Professor of Medicine Division of General Internal Medicine Department
More informationDivision of Vascular Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 2
Vascular Specialist International Vol. 34, No. 4, December 2018 pissn 2288-7970 eissn 2288-7989 Clinical Outcomes of a Preoperative Inferior Vena Cava Filter in Acute Venous Thromboembolism Patients Undergoing
More informationTop Ten Reasons For Failure To Prevent Postoperative Thrombosis
Top Ten Reasons For Failure To Prevent Postoperative Thrombosis Joseph A. Caprini, MD, MS, FACS, RVT, FACCWS Louis W. Biegler Chair of Surgery NorthShore University HealthSystem, Evanston, IL Clinical
More informationCopyright Protected. There is considerable debate over what constitutes. Inferior Vena Cava Filter Placement in Orthopedic Surgery
An Original Study Inferior Vena Cava Filter Placement in Orthopedic Surgery Anne R. Bass, MD, Christopher J. Mattern, MD, MBA, James E. Voos, MD, Margaret G. E. Peterson, PhD, and David W. Trost, MD Abstract
More informationIVC FILTERS: A CASE REPORT REVIEWING THE INDICATIONS FOR PLACEMENT, RETRIEVAL AND ANTICOAGULATION
IVC FILTERS: A CASE REPORT REVIEWING THE INDICATIONS FOR PLACEMENT, RETRIEVAL AND ANTICOAGULATION Resident(s): George Athanasatos Attending(s): Daniel Golwyn Program/Dept: Interventional Radiology CHIEF
More informationInterventional Radiology in Trauma. Vikash Prasad, MD, FRCPC Vascular and Interventional Radiology The Moncton Hospital
Interventional Radiology in Trauma Vikash Prasad, MD, FRCPC Vascular and Interventional Radiology The Moncton Hospital Disclosures None relevant to this presentation Shareholder Johnson and Johnson Goal
More informationTop 5 (or so) Hematology Consults. Tom DeLoughery, MD FACP FAWM. Oregon Health and Sciences University DISCLOSURE
Top 5 (or so) Hematology Consults Tom FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none 1 What I am Talking About
More informationComplications of inferior vena cava filters
Review Article Complications of inferior vena cava filters Simer Grewal, Murthy R. Chamarthy, Sanjeeva P. Kalva Department of Radiology, Division of Interventional Radiology, University of Texas Southwestern
More informationPost-Traumatic Thromboembolism. Pathogenesis, Diagnosis and Prevention M. Margaret Knudson, MD
Post-Traumatic Thromboembolism Pathogenesis, Diagnosis and Prevention M. Margaret Knudson, MD Historical Perspectives A study of protocols of 9,882 postmortem exams including death from injury in the traumatic
More informationExpanding Horizons: AngioVac Suction Thrombectomy at UTHealth
Expanding Horizons: AngioVac Suction Thrombectomy at UTHealth Naveed Saqib, MD Assistant Professor Department of Cardiothoracic and Vascular Surgery McGovern Medical School The University of Texas Science
More informationPREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM International Consensus Statement 2013 Guidelines According to Scientific Evidence Developed under the auspices of the: Cardiovascular Disease Educational
More informationHow to prevent thrombotic diseases? Sergio Fusco, MD
How to prevent thrombotic diseases? Sergio Fusco, MD Geriatric Division - Department of Internal Medicine Ospedale Dell'Angelo - Venice, Italy CONFLICT OF INTEREST DISCLOSURE I have no potential conflict
More informationPictorial review of IVC filters and their complications
Pictorial review of IVC filters and their complications Poster No.: C-1353 Congress: ECR 2014 Type: Educational Exhibit Authors: J. A. Vossen, J. S. Golia, L. Miller, D. Fedele, N. Velasco; Bridgeport,
More informationCURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM. Gordon Lowe Professor of Vascular Medicine University of Glasgow
CURRENT & FUTURE THERAPEUTIC MANAGEMENT OF VENOUS THROMBOEMBOLISM Gordon Lowe Professor of Vascular Medicine University of Glasgow VENOUS THROMBOEMBOLISM Common cause of death and disability 50% hospital-acquired
More informationAspirin as Venous Thromboprophylaxis
Canadian Society of Internal Medicine Nov 2, 2017 Aspirin as Venous Thromboprophylaxis Bill Geerts, MD, FRCPC Thromboembolism Consultant, Sunnybrook HSC Professor of Medicine, University of Toronto Disclosures
More informationPercutaneously Inserted AngioVac Suction Thrombectomy for the Treatment of Filter-Related. Iliocaval Thrombosis
Percutaneously Inserted AngioVac Suction Thrombectomy for the Treatment of Filter-Related Iliocaval Thrombosis Faiz D. Francis, DO; Gianvito Salerno, MD; Sabbah D. Butty, MD Abstract In the setting of
More informationIVC filter retrieval program effects on retrieval rates and number of patients lost to follow-up
IVC filter retrieval program effects on retrieval rates and number of patients lost to follow-up Aliaksei Salei, MD; Joel Raborn, MD; Padma P. Manapragada, MD; Ahmed Kamel Abdel Aal, MD/PhD; AJ Gunn, MD
More informationVenous Thromboembolic Disease Update
Canadian Society of Internal Medicine Annual Meeting Calgary, Alberta, October 2014 Venous Thromboembolic Disease Update Benjamin Bell, MD FRCPC James Douketis, MD FRCPC On Behalf of Thrombosis Canada
More informationDVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center
DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients David Liff MD Oklahoma Heart Institute Vascular Center Overview Pathophysiology of DVT Epidemiology and risk factors for DVT in the
More informationPerforated inferior vena cava filter removal by concurrent femoral and internal jugular vein approaches
www.edoriumjournals.com CLINICAL IMAGES PEER REVIEWED OPEN ACCESS Perforated inferior vena cava filter removal by concurrent femoral and internal jugular vein approaches Raymond Yap, Ankur Sidhu, Mark
More informationInterventional Treatment VTE: Radiologic Approach
Interventional Treatment VTE: Radiologic Approach Hae Giu Lee, MD Professor, Dept of Radiology Seoul St. Mary s Hospital The Catholic University of Korea Introduction Incidence High incidence: 250,000-1,000,000/year
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationPrevention of Venous Thromboembolism in High-Risk Patients
Prevention of Venous Thromboembolism in High-Risk Patients William H. Geerts The prevention of venous thromboembolism (VTE) in patients recovering from major trauma, spinal cord injury (SCI), or other
More informationManagement of Pulmonary Embolism. Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School
Management of Pulmonary Embolism Michael Hooper, M.D., MSc Associate Professor, Pulmonary and Critical Care Medicine Eastern Virginia Medical School I have no conflicts of interest to report. VTE Overview
More informationPulmonary embolism (PE) has often been considered a
Prophylactic Inferior Vena Cava Filters: Do They Make a Difference in Trauma Patients? Robert A. Cherry, MD, FACS, Pamela A. Nichols, BSN, Theresa M. Snavely, BSN, RN, Mauger T. David, PhD, and Frank C.
More informationTHROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY
THROMBOPROPHYLAXIS: NON-ORTHOPEDIC SURGERY OBJECTIVE: To outline a practical approach for the prevention of venous thromboembolism (VTE) in patients undergoing non-orthopedic surgery. BACKGROUND: VTE is
More informationDuration of Anticoagulant Therapy. Linda R. Kelly PharmD, PhC, CACP September 17, 2016
Duration of Anticoagulant Therapy Linda R. Kelly PharmD, PhC, CACP September 17, 2016 Conflicts of Interest No conflicts of interest to report Objectives At the end of the program participants will be
More informationUpdates in Management of Pulmonary Embolism (PE) David Ming, MD Duke Hospital Medicine July 24, 2017 Hilton Head, SC
Updates in Management of Pulmonary Embolism (PE) David Ming, MD Duke Hospital Medicine July 24, 2017 Hilton Head, SC Objectives Highlight clinical features and presentation of acute PE Analyze strategies
More informationARTEMIS. ARixtra (fondaparinux) for ThromboEmbolism prevention in. a Medical Indications Study. NV Organon Protocol 63129
ARTEMIS ARixtra (fondaparinux) for ThromboEmbolism prevention in NV Organon Protocol 63129 a Medical Indications Study Objective To demonstrate efficacy and to assess safety of oncedaily subcutaneous (SC)
More informationDisclosures. Objectives
BRIGHAM AND WOMEN S HOSPITAL Treatment of Massive and Submassive Pulmonary Embolism Gregory Piazza, MD, MS Assistant Professor of Medicine Harvard Medical School Staff Physician, Cardiovascular Division
More informationDiagnosis and Treatment of Pulmonary Embolism: High-Tech versus Low- Tech, which way to go?
Diagnosis and Treatment of Pulmonary Embolism: High-Tech versus Low- Tech, which way to go? Philip S. Wells MD, FRCPC, MSc Professor Chair and Chief, Department of Medicine, University of Ottawa DISCLOSURE
More informationRecent advances in the management of pulmonary embolism. Kodati Rakesh SR Pulmonary medicine
Recent advances in the management of pulmonary embolism Kodati Rakesh SR Pulmonary medicine Clinical decision rules & D dimer Outpatient anticoagulation Thrombolysis Anticoagulation Catheter directed therapies
More informationIntervention for Deep Venous Thrombosis and Pulmonary Embolus
Intervention for Deep Venous Thrombosis and Pulmonary Embolus Michael R. Jaff, DO Paul and Phyllis Fireman Endowed Chair in Vascular Medicine Massachusetts General Hospital Professor of Medicine Harvard
More information10/8/2012. Disclosures. Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines. Goals and Objectives. Outline
Disclosures Making Sense of AT9: Review of the 2012 ACCP Antithrombotic Guidelines No relevant conflicts of interest related to the topic presented. Cyndy Brocklebank, PharmD, CDE Chronic Disease Management
More informationBard Recovery Filter: Evaluation and Management of Vena Cava Limb Perforation, Fracture, and Migration
Bard Recovery Filter: Evaluation and Management of Vena Cava Limb Perforation, Fracture, and Migration Jeffrey E. Hull, MD, and Scott W. Robertson, PhD PURPOSE: To report on the evaluation and management
More informationVenous Thrombo-Embolism. John de Vos Consultant Haematologist RSCH
Venous Thrombo-Embolism John de Vos Consultant Haematologist RSCH overview The statistics Pathogenesis Prophylaxis Treatment Agent Duration Incidental VTE Recurrence of VTE IVC filters CVC related thrombosis
More informationComparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project
Comparison of Venothromboembolism Prophylaxis Practices in a Winnipeg Tertiary Care Hospital to Chest Guidelines: A Quality Improvement Project Dr. Jonathan Laxton, FRCPC, R5 GIM University of Manitoba
More informationCase-based topics to touch on Beware of devices that sit in veins. Asymptomatic PE management conundrum. nd Should we be testing for hypercoagulabilit
SMALL FEEDINGS IN VENOUS THROMBOEMBOLISM ACP CHAPTER MEETING TURF VALLEY, FEBRUARY, 2012 Daniel J. Brotman, MD, FACP, FHM Director, Hospitalist Program, Johns Hopkins Hospital Associate Professor of Medicine
More informationResults from RE-COVER RE-COVER II RE-MEDY RE-SONATE EXECUTIVE SUMMARY
Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of recurrent DVT and PE Results from
More informationDuration of Therapy for Venous Thromboembolism
Duration of Therapy for Venous Thromboembolism Michael B Streiff, MD FACP Associate Professor of Medicine and Pathology Medical Director, Johns Hopkins Anticoagulation Service Chairman, VTE Guideline Committee
More informationInferior Vena Cava Filter Migration to the Right Ventricle: A Case Report and Review of Filter Migration and Misdeployment
Elmer Press Case Report Inferior Vena Cava Filter Migration to the Right Ventricle: A Case Report and Review of Filter Migration and Misdeployment Jason Dreyer a, d, Ketul Patel b, Huma Shujaat b, Michael
More informationFocus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018
Focus: l embolia polmonare Per quanto la terapia anticoagulante orale? Giulia Magnani 27 Gennaio, 2018 NO DISCLOSURE Pulmonary Embolism Venous thromboembolism (VT) is the third most common cause of cardiovascular
More informationComplications of Inferior Vena Caval Filters
Complications of Inferior Vena Caval Filters Thuong G. Van Ha, M.D. 1 ABSTRACT Inferior vena caval filters have been shown to be effective in the prevention of pulmonary embolism, with low morbidity and
More informationDVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE)
DVT PROPHYLAXIS IN HOSPITALIZED MEDICAL PATIENTS SAURABH MAJI SR (PULMONARY,MEDICINE) Introduction VTE (DVT/PE) is an important complication in hospitalized patients Hospitalization for acute medical illness
More informationWhat is the impact of Superficial Vein Thrombosis?
What is the impact of Superficial Vein Thrombosis? Athanasios D. Giannoukas MD, MSc(Lond.), PhD(Lond.), FEBVS Professor of Vascular Surgery Faculty of Medicine, University of Thessalia, Greece Chairman,
More informationUnderstanding thrombosis in venous thromboembolism. João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal
Understanding thrombosis in venous thromboembolism João Morais Head of Cardiology Division and Research Centre Leiria Hospital Centre Portugal Disclosures João Morais On the last year JM received honoraria
More informationMeissner MH, Gloviczki P, Comerota AJ, Dalsing MC, Eklof BG, Gillespie DL, et al. J Vasc Surg. 2012;55:
Early thrombus removal strategies for acute deep venous thrombosis: Clinical Practice Guidelines of the Society for Vascular Surgery and the American Venous Forum Meissner MH, Gloviczki P, Comerota AJ,
More informationDENOMINATOR: All surgical patients aged 18 years and older undergoing procedures for which VTE prophylaxis is indicated in all patients
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2017 OPTIONS FOR INDIVIDUAL MEASURES:
More informationPerioperative Management of the Anticoagulated Patient
Perioperative Management of the Anticoagulated Patient Citywide Resident Perioperative Medical Consultation Conference 5/5/17 Matthew Eisen, MD Director, Anticoagulation Services MetroHealth Medical Center
More informationVTE Management in Surgical Patients: Optimizing Prophylaxis Strategies
VTE Management in Surgical Patients: Optimizing Prophylaxis Strategies VTE in Surgical Patients: Recognizing the Patients at Risk Pathogenesis of thrombosis: Virchow s triad and VTE Risk Hypercoagulability
More informationVersatility and Proven Safety
Versatility and Proven Safety Indicated for: Temporary or Permanent placement Standard or Over-The-Wire Delivery Jugular, Femoral, Antecubital, and Popliteal Access > Proven Safety Initial Clinical Trial
More informationGetting Started Kit VENOUS THROMBOEMBOLISM PREVENTION. Section 2: Evidence-Based Appropriate VTE Prophylaxis
Reducing Harm Improving Healthcare Protecting Canadians VENOUS THROMBOEMBOLISM PREVENTION Getting Started Kit Section 2: Evidence-Based Appropriate VTE Prophylaxis January 2017 www.patientsafetyinstitute.ca
More informationInferior vena cava filters: current best practices
J Thromb Thrombolysis (2015) 39:315 327 DOI 10.1007/s19-015-1187-5 Inferior vena cava filters: current best practices Anita Rajasekhar Published online: 14 February 2015 Ó Springer Science+Business Media
More informationVenous thrombotic, thromboembolic, and mechanical complications after retrievable inferior vena cava filters for major trauma
British Journal of Anaesthesia 114 (1): 63 9 (2015) Advance Access publication 30 June 2014. doi:10.1093/bja/aeu195 CLINICAL PRACTICE Venous thrombotic, thromboembolic, and mechanical complications after
More informationCPT only copyright 2014 American Medical Association. All rights reserved. 12/23/2014 Page 66 of 593
Measure #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2015 PQRS OPTIONS FOR INDIVIDUAL MEASURES:
More informationEXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS
EXTENDING VTE PROPHYLAXIS IN ACUTELY ILL MEDICAL PATIENTS Samuel Z. Goldhaber, MD Director, VTE Research Group Cardiovascular Division Brigham and Women s Hospital Professor of Medicine Harvard Medical
More informationPenetration of Celect Inferior Vena Cava Filters: Retrospective Review of CT Scans in 265 Patients
Vascular and Interventional Radiology Original Research Zhou et al. CT of Celect Inferior Vena Cava Filter Penetration Vascular and Interventional Radiology Original Research Dayong Zhou 1,2 Eunice Moon
More informationJoint Theater Trauma System Clinical Practice Guideline
THE PREVENTION OF DEEP VENOUS THROMBOSIS IVC Filter Original Release/Approval 25 Dec 2004 Note: This CPG requires an annual review. Reviewed: Mar 2012 Approved: 24 Apr 2012 Supersedes: The Prevention of
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #23 (NQF 0239): Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients) National Quality Strategy Domain: Patient Safety 2018 OPTIONS FOR INDIVIDUAL MEASURES:
More informationDisclosures. DVT: Diagnosis and Treatment. Questions To Ask. Dr. Susanna Shin - DVT: Diagnosis and Treatment. Acute Venous Thromboembolism (VTE) None
Disclosures DVT: Diagnosis and Treatment None Susanna Shin, MD, FACS Assistant Professor University of Washington Acute Venous Thromboembolism (VTE) Deep Venous Thrombosis (DVT) Pulmonary Embolism (PE)
More informationFrom the Society for Vascular Surgery
From the Society for Vascular Surgery Role of prophylactic temporary inferior vena cava filters placed at the ICU bedside under intravascular ultrasound guidance in patients with multiple trauma David
More informationManagement of Cancer Associated Thrombosis (CAT) where data is lacking. Tim Nokes Haematologist, Derriford Hospital, Plymouth
Management of Cancer Associated Thrombosis (CAT) where data is lacking Tim Nokes Haematologist, Derriford Hospital, Plymouth Contents Overview of the statistics and aetiology for Cancer Associated Thrombosis
More informationObjectives. Venous Thromboembolism (VTE) Prophylaxis. Case VTE WHY DO IT? Question: Who Is At Risk?
Objectives Venous Thromboembolism (VTE) Prophylaxis Rishi Garg, MD Department of Medicine Identify patients at risk for VTE Options for VTE prophylaxis Current Recommendations (based on The Seventh ACCP
More information1. SCOPE of GUIDELINE:
Page 1 of 35 CLINICAL PRACTICE GUIDELINE: Venous Thromboembolism (VTE) Prevention Guideline: Thromboprophylaxis AUTHORIZATION: VP, Medicine Date Approved: May 17, 2012 Date Revised: Vancouver Coastal Health
More informationMedical Patients: A Population at Risk
Case Vignette A 68-year-old woman with obesity was admitted to the Medical Service with COPD and pneumonia and was treated with oral corticosteroids, bronchodilators, and antibiotics. She responded well
More informationAN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS
The West London Medical Journal 2010 Vol 2 No 4 pp 19-24 AN AUDIT: THROMBOPROPHYLAXIS FOR TOTAL HIP REPLACEMENT PATIENTS AT NORTHWICK PARK AND CENTRAL MIDDLESEX HOSPITALS Soneji ND Agni NR Acharya MN Anjari
More informationRisk factors for DVT. Venous thrombosis & pulmonary embolism. Anticoagulation (cont d) Diagnosis 1/5/2018. Ahmed Mahmoud, MD
Risk factors for DVT Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationVenous thrombosis & pulmonary embolism. Ahmed Mahmoud, MD
Venous thrombosis & pulmonary embolism Ahmed Mahmoud, MD Risk factors for DVT Surgery ; post op especially for long cases, pelvic operations (THR), Trauma ; long bone fractures, pelvic fractures (posterior
More informationOctober 2017 Pulmonary Embolism
October 2017 Pulmonary Embolism Prof. Ahmed BaHammam, FRCP, FCCP Professor of Medicine College of Medicine King Saud University 1 Objectives Epidemiology Pathophysiology Diagnosis Massive PE Treatment
More informationEpidemiology of Thrombosis in Patients with Malignancy. Cancer and Venous Thromboembolism. Chew HK, Arch Int Med, Feb Blom et al, JAMA, Feb 2005
Cancer and Venous Thromboembolism Objectives 1. Epidemiology of thrombosis in patients with malignancy 2. Anticancer agents and thrombosis 3. Current treatment protocols at UHN 4. Prevention of DVT 5.
More informationControversies in Venous Thromboembolism
Controversies in Venous Thromboembolism Menaka Pai, BSc MSc MD FRCPC Assistant Professor, Department of Medicine, McMaster University Associate Member, Department of Pathology and Molecular Medicine, McMaster
More informationHISTORICALLY, INSERTION
ORIGINAL INVESTIGATION A Population-Based Study of Inferior Vena Cava Filters in Patients With Acute Venous Thromboembolism Frederick A. Spencer, MD; Shannon M. Bates, MD; Robert J. Goldberg, PhD; Darleen
More informationAnticoagulation for prevention of venous thromboembolism
Anticoagulation for prevention of venous thromboembolism Original article by: Michael Tam Note: updated in June 2009 with the eighth edition (from the seventh) evidence-based clinical practice guidelines
More informationVIRTUS: Trial Design and Primary Endpoint Results
VIRTUS: Trial Design and Primary Endpoint Results Mahmood K. Razavi, MD St. Joseph Cardiac and Vascular Center Orange, CA, USA IMPORTANT INFORMATION: These materials are intended to describe common clinical
More informationPharmacy Prior Authorization
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Anticoagulant Injectable (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
More informationSociety of Trauma Nurses TraumaCon 03/22/2018
Prophylaxis Against Venous Thromboemblism (VTE) in Pediatric Trauma Society of Trauma Nurses TraumaCon 03/22/2018 Arash Mahajerin, MD, MSCr Hematology, CHOC Children s Specialists Orange, CA Disclosure
More information